Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC)

E. F. Smit, M. A. Socinski, B. P. Mullaney, S. P. Myrand, E. Powell, P. Lorigan, C. Kaiser, S. C. Guba, N. Thatcher

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article number8030
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2009
Event45th Annual Meeting of the American-Society-of-Clinical-Oncology - Florida, United States
Duration: 29 May 20092 Jun 2009

Cite this